# Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

> **NCT04140409** · PHASE4 · TERMINATED · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 10 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Carcinoid Syndrome

## Interventions

- **DRUG:** Sandostatin

## Key facts

- **NCT ID:** NCT04140409
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-02
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-09-19
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2019-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04140409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04140409, "Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04140409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*